Introduction: We describe the safety, tolerability, and efficacy of protease inhibitor (PI) containing highly active antiretroviral therapy (HAART) among patients switching from nonnucleoside reverse transcriptase inhibitor (NNRTI)-based HAART from a clinical setting in South India. Methods: We assessed a prospective cohort of 91 HIV-infected patients with at least 12 months of clinical follow-up on second-line ritonavir-boosted PI-based therapy between August 2003 and December 2008. Results: More than three fourths of patients met the World Health Organization (WHO) criteria for immunological failure at the time of switch. The median time to switch was 758 days. Patients demonstrated consistent increases in their CD4 counts during the first 12 months, by which time the median CD4 count was 322 cells/mm 3 . The most common adverse events within the first year after switch were nausea (14.8%), lipodystrophy (10.4%), and peripheral neuropathy (7.0%). Patients switching to atazanavir (ATV)-based regimens compared to those switching to indinavir (IDV)-based regimens had similar immunological and clinical outcomes. Conclusions: Given the therapeutic success of using second-line PI-containing HAART after experiencing treatment failure, further efforts must be taken to expand access to second-line HAART so that more patients can benefit from these drugs.
Introduction
As access to highly active antiretroviral therapy (HAART) has continued to increase in resource-limited settings, the growing need for second-line regimens has become a priority as patients develop treatment failure. 1, 2 Detection of first-line treatment failure in resource-limited settings currently relies on clinical and immunological criteria. 3 Patients can be switched to second-line HAART following the prolonged development of drug-resistant mutations and unsuppressed viral load, further jeopardizing the provision of second-line HAART. 4 Additional barriers to the further roll-out of second-line protease inhibitors (PI) include the lack of adequate boosted regimens, problems with maintaining patient adherence, and the continued high cost. 5 To date, data remain very limited from resource-limited settings assessing the use and outcomes of PI-based second-line regimens. 6, 7 In an earlier study, we reported shortterm outcomes on a smaller cohort of patients initialing second-line PI-based HAART. 8 Clinical data are needed to better understand long-term treatment strategies of switching patients to second-line therapy to more optimally switch and manage HAART-experienced patients in resourcelimited settings. The current study describes the safety, tolerability, and efficacy of PI-containing HAART among patients switching from nonnucleoside reverse transcriptase inhibitor (NNRTI)-based HAART at a tertiary care HIV center in South India.
Methods Setting
Since 1996, YRG Center for AIDS Research and Education (YRG CARE), VHS, Chennai, has provided a continuum of care for over 12 000 HIV-infected individuals. All patients are treated according to World Health Organization (WHO) treatment guidelines. Patients are advised to initiate HAART before CD4 counts reach below 200 cells/mm 3 or when CD4 counts range between 200 and 350 cells/mm 3 with an AIDSdefining illness. Patients were seen every 3 months or as clinically indicated. Current Indian treatment guidelines advised for the initiation of ritonavir (RTV) boosted second-line PIs, such as atazanavir (ATV), saquinavir (SQV), lopinavir (LPV), and indinavir (IDV), combined with 2 NRTIs after treatment failure of NNRTI-based first-line therapy, 9 which is in accordance with current WHO and US Department of Health and Human Services (DHHS) recommendations. 7
Participants
Patients who were older than 18 years of age and who had initiated second-line PI-based HAART after experiencing treatment failure on a first-line NNRTI-based regimen were included in the current analysis. Patients were switched only after a minimum of 6 months on first-line HAART. Among patients who switched to a second-line PI-containing regimen, only those with at least 12 months of follow-up on second-line therapy were included in the current study. Among the 451 patients switching to a PI-based regimen, 336 patients were excluded due to a lack of adequate follow-up time to date.
Clinical Variables Assessed
Analyses were executed using the YRG CARE Chennai HIV Observational Database. This database updated daily collects data on demographics; clinical assessments including data related to the occurrence of new opportunistic infections; current treatment regimens and adverse events (AE); as well as laboratory data, including hemoglobin, liver, and renal function tests, CD4 counts, and plasma viral load (PVL). Genotyping was done in select patients. In accordance with WHO guidelines, patients received laboratory monitoring at least every 6 months after initiating therapy. 3 
Definitions
Treatment ''Switching'' was used to refer to those patients who modified therapy to a different drug class (ie, NNRTI to PI) because of clinical or immunological treatment failure. Treatment substitution was used to refer to patients modifying regimens within the same drug class. The clinical criterion for failure was the development of an AIDS-defining illness after at least 3 months on HAART. According to WHO treatment guidelines, immunologic failure was defined as a decrease in CD4 to baseline (or below) after 6 months of therapy, a persistent CD4 below 100 cells/mm 3 after 6 months of therapy, or a 50% decline from the on-treatment peak CD4 value. 10 Modification or discontinuation of therapy was evaluated in association with immunologic or HIV-related clinical indicators of treatment failure and treatment-associated toxicities.
Statistical Analysis
Descriptive statistics were calculated with mean and standard deviation for variables that were normally distributed; and the median and interquartile range (IQR) were calculated for variables influenced by extreme values. To compare proportions, chi-square (w 2 ) statistics were used, and the Mann-Whitney U test was used to compare median durations. Statistical analyses were performed with SPSS software (version 13.0; SPSS, Chicago, Illinois). A P value less than .05 was considered statistically significant.
Results
Between February 1996 and December 2008, 3221 patients had initiated first-line HAART, and between August 2003 and December 2008, 451 patients initiated a PI-containing regimen after switching from an NNRTI-based HAART regimen. Among these patients, 91 had at least 12 months of clinical follow-up on second-line therapy and only these patients are included in the current analysis. Three fourths of patients were male, and the median age was 35 years (see Table 1 ). The primary mode of transmission was heterosexual intercourse (90%). The median body mass index (BMI) was 19.8 (IQR: 16.5-22.5).
The median CD4 count at the time of enrolling into care was 107 cells/mm 3 (IQR: 56-170) and the median hemoglobin was 11.4 g/dL (IQR: 9.5-12.6). The most common first-line regimens included zidovudine (AZT) þ (lamivudine; 3TC) þ nevirapine (NVP; 38%), 3TC þ stavudine (d4T) þ NVP (33%), and AZT þ 3TC þ efavirzenz (EFV; 8%); the distribution of first-line regimens immediately prior to treatment switch was broadly the same. The median time to switch was 758 days (IQR: 374-1513), and the median time on the immediate NNRTI-based regimen prior to switch was 363 days (IQR: 176-651).
More than three fourths (80%) of patients met one of WHO definitions for immunological failure at the time of switch. An additional 10% of patients experienced clinical failure at the time of switch. At the time of switch, the main reasons for stopping first-line NNRTI regimens included decline in CD4 count (23%) and drug resistance (23%). At the time of switch, the median CD4 count was 119 cells/mm 3 (IQR: 52-231). Half of the patients initiated an ATZ-containing PI regimen (48%), 45% an IDV-containing PI regimen, and 7% an LPVcontaining regimen. The primary NRTI-backbone consisted of a tenofovir (TDF) þ emtricitabine (FTC) regimen (56%), 3TC þ didanosine (ddI; 23%), and AZT þ ddI (15%). All patients were on an RTV-boosted PI regimen. Close to a tenth (10%) of patients were substituted to an alternative PI regimen within 12 months of switching.
Patients experienced a significant rise in their CD4 counts between the time of switch (119 cells/mm 3 ; IQR: 52-231) to 3 months (274 cells/mm 3 ; IQR: 203-357) on a PI-containing regimen (P ¼ .041 Figure 1 ). Although not statistically significant increases, patients also demonstrated consistent immunological gains after 6 months (322 cells/mm 3 ; IQR: 202-401) and 12 months after switch (322 cells/mm 3 ; IQR: 225-482). The most common adverse events within the 12 months after switch were nausea (14.8%), lipodystrophy (10.4%), peripheral neuropathy (7.0%), and diarrhea (6.1%). The most common opportunistic infections within the 12 months after switch were oral candidiasis (27.0%), pulmonary tuberculosis (6.1%), herpes simplex (7.8%), and herpes zoster (3.5%). One patient died during the 12 months of follow-up. After 12 months of treatment, the most common reasons for stopping therapy were an adverse event (7.0%) and decline in absolute CD4 count (4.3%).
We compared patients switching to ATV-based regimen (N ¼ 44) in relation to patients switching to IDV-based regimens (N ¼ 41). Both groups of patients had similar types of NRTI-based regimens, median CD4 counts at the time of switch, and immunological outcomes over the 12 months of follow-up. Patients on IDV-based regimens had significantly longer periods of follow-up on second-line therapy compared to patients on ATV-based regimens (615 vs 493 days; P < .0001). More patients on IDV-based regimens substituted for an alternative PI-based regimen within 12 months of switch compared to patents on ATV-based regimens (12.2% vs 6.8%). After 12 month of follow-up, an additional 5 patients substituted from an IDV to an ATV-based regimen. Both groups of patients had similar distributions of adverse events and opportunistic infections.
Discussion
The current study demonstrates that after 12 months on second-line PI-containing HAART, patients demonstrated good immunological outcomes and few had developed serious opportunistic infections and adverse events. The findings of the current study can assist clinicians in the management of patients who are increasingly switching to second-line regimens after first-line treatment failure in resource-limited settings. Given the therapeutic success of using these agents, further efforts must be made to improve diagnostic tools for promptly detecting treatment failure and measures must be taken to expand access and adherence so that more patients can benefit from these drugs.
The major reason for treatment switching was immunological failure. Due to the lack of routine virological monitoring, diagnosis of treatment failure was dependent on clinical and immunological criteria. There have been concern that the accumulation of resistant mutations due to prolonged exposure to a failing first-line regimen, particularly thymidine analogue mutations (TAMs), could limit the effectiveness of second-line ART regimens. 4, 11 In the current study, over a half of patients were initiated on a TDF-based second-line regimen and over a third of patients were on ddI-based regimen, both of which do not select for TAMs. However, a sixth of patients received a ddI/AZT combination, which is rarely used in the developed world due to concerns over the emergence of further TAMs and multiplenucleoside mutations. Detection of early treatment failure based on virological monitoring would ensure that patients avoid severe clinical complications and prevent unnecessary early switching. 12 IDV-based PI regimens were the first available in India, and later generic boosted ATV-and LPV-based regimens were made available. Patients now initiate an ATV-or LPV-based regimen at the time of switch. In the current study, patients had been increasingly subsisted from IDV-to ATV-based regimens. Patients who were initiated on boosted ATV-and IDV-regimens had broadly similar immunonological and clinical outcomes. Our findings are similar to a recent study from the Medicins Sans Frontieres (MSF) treatment program that demonstrated good immunological outcomes on second-line therapy, but of concern was that more than half of the patients were still at risk of significant opportunistic infections (CD4 count < 200 cells/mm 3 ) even 12 months after switch. 6 Unlike our study where all patients were switched to boosted PIregimens, in the MSF study, more than two fifths of patients were put on a NFV-based PI regimen, which are less effective than RTV-boosted PI regimens. 13 As a larger number of patients initiate ART across the developing world, failure of first-line treatment is inevitable among at least some patients. 14 It has been estimated that in the near future, the rate of 5-year switching could range between 5% to 40% based on the individual country, 15 but only a quarter of patients in resource-limited settings on second-line therapy are on drug combinations recommended by current WHO guidelines, in contrast to patients on first-line HAART where almost all patients are on recommended combinations. 15 There is a need to rapidly expand the formulary of second-line PI regimens that are in concordance with WHO guidelines as part of national treatment programs. 16 Given the good treatment outcomes of patients initiating second-line PI containing HAART, further efforts are needed to improve the timely diagnosis of treatment failure on first-line therapy and expand access to second-line regimens.
